Selective Tumor Retention. Predictable Outcomes.

Platform leverages a clinically validated macrocycle used in >1000 patients creating confirmed regulatory and clinical efficiencies.

Concentrating drug activity where it’s needed (e.g., tumor tissue) while limiting systemic exposure.

Enable novel drug conjugates that do not rely on traditional antibody targeting. Offers predictable pharmacokinetics and stability, supporting more durable responses.